Physician profile
Leo A Smith
NPI 1023265816
$3,997.23
in general payments reported to CMS, 2019-2025
33 companies · $233 in 2025
The $233 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,168 · 2020: $365 · 2021: $82.14 · 2022: $301 · 2023: $607 · 2024: $242 · 2025: $233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,081.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,081.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $662.11 | 2019-2025 | |
| Amgen INC. | $556.65 | 2019-2025 | Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $377.48 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $308.62 | 2019-2024 | Airsupra, Breztri |
| Glaxosmithkline, LLC. | $248.93 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Allergan, INC. | $219.70 | 2019 | |
| Novo Nordisk INC | $189.54 | 2019-2025 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $183.07 | 2019-2023 | Xarelto |
| Astellas Pharma US INC | $158.48 | 2019-2023 | Myrbetriq, Veozah |
| Teva Pharmaceuticals USA, INC. | $153.56 | 2019-2020 | |
| Progenics Pharmaceuticals, INC. | $116.16 | 2022 | |
| Abbvie INC. | $83.08 | 2023-2025 | Vraylar, Ubrelvy |
| Lilly USA, LLC | $75.39 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $71.78 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $52.56 | 2019-2025 | Rexulti |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $50.17 | 2019-2020 | |
| Sanofi Pasteur INC. | $46.67 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $45.27 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.51 | 2019 | |
| Organon LLC | $41.38 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.53 | 2023 | |
| Edwards Lifesciences Corporation | $35.02 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $30.45 | 2019 | |
| Sanofi-Aventis U.S. LLC | $27.97 | 2025 | |
| Viiv Healthcare Company | $27.05 | 2024 | Apretude |
| Boston Scientific Corporation | $22.97 | 2023 | Watchman Access System |
| Biohaven Pharmaceutical Holding Company Ltd. | $22.88 | 2022 | |
| Alnylam Pharmaceuticals INC. | $22.17 | 2023 | Givlaari |
| Shield Therapeutics INC | $20.45 | 2023 | Accrufer |
| E.R. Squibb & Sons, L.L.C. | $19.09 | 2019 | |
| Daiichi Sankyo INC. | $17.60 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $14.06 | 2025 | |
| Therapeuticsmd, INC. | $13.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leo Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.